![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Analysis of the EIAV Rev-Responsive Element (RRE) Reveals a Conserved RNA Motif Required for High Affinity Rev Binding in Both HIV-1 and EIAV 1Bioinformatics and Computational Biology Program, Department of Genetics, Development and Cell Biology, Iowa State University, Ames, Iowa, United States of America 2Department of Biology, University of Rochester, Rochester, New York, United States of America 3Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington, United States of America Dong-Yan Jin, Editor University of Hong Kong, China * E-mail: jhlee777/at/iastate.edu Conceived and designed the experiments: JL. Performed the experiments: JL. Analyzed the data: JL. Contributed reagents/materials/analysis tools: JL DD GC SC. Wrote the paper: JL DD SC. Received February 11, 2008; Accepted April 15, 2008. This article has been cited by other articles in PMC.Abstract A cis-acting RNA regulatory element, the Rev-responsive element (RRE), has essential roles in replication of lentiviruses, including human immunodeficiency virus (HIV-1) and equine infection anemia virus (EIAV). The RRE binds the viral trans-acting regulatory protein, Rev, to mediate nucleocytoplasmic transport of incompletely spliced mRNAs encoding viral structural genes and genomic RNA. Because of its potential as a clinical target, RRE-Rev interactions have been well studied in HIV-1; however, detailed molecular structures of Rev-RRE complexes in other lentiviruses are still lacking. In this study, we investigate the secondary structure of the EIAV RRE and interrogate regulatory protein-RNA interactions in EIAV Rev-RRE complexes. Computational prediction and detailed chemical probing and footprinting experiments were used to determine the RNA secondary structure of EIAV RRE-1, a 555 nt region that provides RRE function in vivo. Chemical probing experiments confirmed the presence of several predicted loop and stem-loop structures, which are conserved among 140 EIAV sequence variants. Footprinting experiments revealed that Rev binding induces significant structural rearrangement in two conserved domains characterized by stable stem-loop structures. Rev binding region-1 (RBR-1) corresponds to a genetically-defined Rev binding region that overlaps exon 1 of the EIAV rev gene and contains an exonic splicing enhancer (ESE). RBR-2, characterized for the first time in this study, is required for high affinity binding of EIAV Rev to the RRE. RBR-2 contains an RNA structural motif that is also found within the high affinity Rev binding site in HIV-1 (stem-loop IIB), and within or near mapped RRE regions of four additional lentiviruses. The powerful integration of computational and experimental approaches in this study has generated a validated RNA secondary structure for the EIAV RRE and provided provocative evidence that high affinity Rev binding sites of HIV-1 and EIAV share a conserved RNA structural motif. The presence of this motif in phylogenetically divergent lentiviruses suggests that it may play a role in highly conserved interactions that could be targeted in novel anti-lentiviral therapies. Introduction Retroviruses, including the lentiviruses HIV-1 and EIAV, employ a variety of mechanisms to regulate the expression of alternatively spliced viral mRNAs [1], [2]. The presence of suboptimal splice sites allows for differential expression of several mRNAs from a single pre-RNA. Regulatory cis-acting RNA sequences that either enhance or repress recognition of a splice site by the host cellular splicing factors often play critical roles in regulating splice-site selection [3], [4]. In some retroviruses, viral pre-mRNAs contain constitutive transport elements (CTE) that are recognized by cellular proteins to facilitate nuclear export of incompletely spliced viral mRNAs [5]. Other retroviruses encode Rev/Rex proteins that act in trans to regulate nuclear export of unspliced or incompletely spliced mRNAs required for expression of structural and enzymatic proteins as well as progeny viral RNA genomes [6]–[8]. The Rev/Rex RNA export pathway has been best characterized in HIV-1 [9]. After entering the nucleus, the HIV-1 Rev protein binds to a specific cis-acting element, termed the Rev-responsive element (RRE), within the viral pre-mRNA [10], [11], multimerizes [12], [13] and then facilitates nuclear export of incompletely spliced viral mRNA via the Crm1 nuclear export pathway [14], [15]. Discrete functional domains within Rev mediate nuclear localization, RRE binding and multimerization, and nuclear export. The HIV-1 RRE is a highly structured RNA located at the junction between the SU (gp120) and TM (gp41) domains of the env gene [11], [16], [17]. Biochemical and biophysical experiments have implicated specific stem-loop structures in Rev binding and multimerization [18]–[20]. Because the Rev-dependent export pathway plays an essential role in HIV-1 replication, disruption of the Rev-RRE interactions is an attractive target for design of effective antiviral therapies [21], [22] All lentiviruses utilize the Rev-dependent, Crm1-mediated export pathway for expression of incompletely spiced mRNAs. There is no conservation among the lentiviral RREs at the RNA sequence level; however, the RRE regions of several primate and non-primate lentiviral genomes map to the SU/TM junction in env gene [11], [16], [17], [23], [24]. In addition, computational analyses have suggested that several of the lentiviral RREs may share RNA secondary structural elements [25]. Equine infectious anemia virus (EIAV) is one of the most divergent members of the subfamily [26]. EIAV Rev (ERev) is functionally homologous with other lentivirus Revs and utilizes the Crm1 pathway for export of incompletely spliced mRNAs, yet EIAV differs from most lentiviruses in structural and functional features of Rev and RRE. EIAV therefore offers an opportunity for comparative analysis of the molecular interactions important in regulation of lentiviral gene expression. EIAV Rev is a 165 amino acid protein translated from exons 3 and 4 of a multiply spliced, four-exon, bicistronic mRNA that also encodes the trans-activating protein, Tat (Figure 1
The EIAV RRE (ERRE) differs from other lentiviral RREs with respect to location and function. The ERRE is located in a 555 nt region near the 5′ end of env, which spans exon 3 of the Tat-Rev mRNA [29], [31], [33], [34]. A 57 nt sequence encompassing the ESE within exon 3 was shown to bind GST-Rev and to act as a functional RRE in a heterologous nuclear export assay system [29]; however, nuclear export activity of the 57 nt “minimal ERRE” was reduced compared to the full-length ERRE [34]. Mutational analyses of the 555 nt ERRE demonstrated that purine-rich sequences within exon 3 function as both an ESE and an RRE [30], [32], [34]. The ERRE thus plays an important role in the complex interactions between viral pre-mRNAs, the viral Rev protein, and cellular splicing factors, to mediate alternative splicing and regulation of viral gene expression [30]–[32], [35]. In this paper, we investigate the RNA structure of the EIAV RRE and its interactions with the Rev protein. We propose an RNA secondary structure model for the essential RRE in EIAV, based on a combination of secondary structure prediction and chemical probing experiments. We present detailed in vitro footprinting analysis of EIAV Rev-RRE complexes, and identify two distinct domains within the essential RRE that undergo significant structural transitions upon Rev binding. Computational analyses identified an RNA secondary structural motif within the high affinity Rev-binding sites of both HIV-1 and EIAV that is present within the mapped RREs of four additional lentiviruses. The discovery of a conserved recognition element for lentiviral Rev-RRE interactions lays the groundwork for investigating highly conserved RNA-protein interactions that could be targeted in novel anti-lentiviral therapies. Results Probing the RNA secondary structure of the ERRE The secondary structure of the ERRE was analyzed using a combination of computational and experimental approaches. Figure 2A
To further refine and validate the RRE secondary structure models, we used available sequence information from EIAV variants to perform covariation analyses, using RNAalifold [41]. RNAalifold can incorporate covariation information from a collection of aligned RNA sequences, in addition to experimental constraint data, as input. Thus, the algorithm determines a consensus RNA secondary structure based on thermodynamic considerations and then evaluates the compatibility of observed sequence covariations with that secondary structure. Experimental constraints are used in the final step to identify an optimized RNA secondary structure. A total of 140 different EIAV SU variant sequences [42] that overlap the ERRE were used to generate a multiple sequence alignment for computing ribonucleotide covariation frequencies within the ERRE. The secondary structure generated by RNAalifold is shown in Figure 3
EIAV Rev “footprints” two regions within the ERRE Previous experiments had implicated the purine-rich ESE within the ERRE as a primary binding site for EIAV Rev protein [29], [32]. To obtain detailed information regarding the interaction of EIAV Rev with ERRE sequences and structural motifs, we performed RNA “footprinting” experiments, using chemical probing and primer extension analysis [43], [44]. Three different chemical reagents were used to compare the accessibilities of ribonucleotides in the ERRE to modification in the presence or absence of bound ERev. Hydroxyl radicals were used to monitor cleavages in the sugar-phosphate backbone, and kethoxal (which modifies N1 and N2 of guanines) and DMS (which methylates N1 of adenines and N3 of cytosines) were employed as base-specific probes. The folded ERRE RNA alone or preformed ERev-ERRE complexes were subjected to modification by each chemical reagent. Primer extension by reverse transcriptase was used to identify the chemically-modified ribonucleotides in the ERRE sequence. In ladders of 32P-labeled primer extension products visualized by denaturing polyacrylamide gel electrophoresis, sites of modification correspond to a “stop” or an enhanced band located one position downstream (3′) of the band corresponding to the modified ribonucleotide site. A summary of the footprinting results is shown in Figure 4
RBR-1: Rev binding induces structural changes both within the ESE in ERRE and in adjacent single-stranded regions Within RBR-1, corresponding to the 5′ terminal region of the ERRE, several purine-rich regions and GAR (guanine-adenine-purine) motifs have been identified as binding sites for the host splicing factor, SF2/ASF [31], [45]. The purine-rich regions PuA and PuB, in particular, have been shown to bind both EIAV Rev and SF2/ASF in electrophoretic mobility shift assays [27], [29], [31], [32]. To obtain more detailed footprinting information for this region, we systematically analyzed changes in the relative extent of ribonucleotide modification using titration experiments, in which ERev-ERRE complexes were formed with increasing amounts of purified EIAV Rev protein (Figure 5A Within loop B, numerous changes in ribonucleotide accessibilities were detected as increasing amounts of EIAV Rev bound, especially in the PuA and PuB regions (Figure 5 Although the region corresponding to loop A, formed by nt 172 to 202, had not previously been implicated in EIAV Rev binding, our footprinting analyses revealed significantly enhanced reactivities of ribonucleotides in this loop. Therefore, we conclude that within RBR-1, in addition to a region within loop B that encompasses previously identified purine-rich PuA and PuB motifs in the ESE, a purine-rich motif in within loop A also undergoes significant structural rearrangement upon Rev binding. RBR-2: A newly identified Rev-binding region in ERRE corresponds to a high affinity binding site By monitoring nucleotide accessibility changes in response to Rev binding across the entire ERRE sequence, we were able to identify RBR-2, a region that had not been previously implicated in Rev binding, located approximately 100 nt downstream from RBR-1. Hydroxyl radical probing identified several regions within loops C and D that are strongly protected from hydroxyl radical cleavage upon EIAV Rev binding (Figure 6 The discovery of interactions between EIAV Rev and RBR-2 is consistent with previous reports that the complete 555 nt ERRE has more functional activity in vivo than several shorter ERRE-derived constructs that encompass the ESE region but lack RBR-2 [29]. We hypothesize that Rev-binding sites within RBR-2 are, in fact, the functional elements “missing” in shorter constructs that retain less activity than the complete ERRE in vivo. Direct in vitro binding affinity measurements support this interpretation: purified ERev binds RNAs that contain both RBR-1 and RBR-2 with an estimated Kd = 19 nM, whereas RNAs that lack RBR-2, but still contain RBR-1, have ~25-fold lower affinity, Kd = 5.2 µM (Figure S1, Supporting Information), indicating that RBR-2 is required for high affinity binding of EIAV Rev to the ERRE.Conservation of ERRE sequences suggests preservation of RNA structural elements An analysis of 178 HIV-1 variant sequences revealed that RNA sequences corresponding to the RRE are highly conserved, most likely as a result of evolutionary pressure for maintenance of both the protein sequence encoded by the gp160 gene (within which the HIV-1 RRE is embedded) and the RNA secondary structure of the RRE [46]. To investigate potential selective pressure for maintaining RNA structural elements within EIAV ERRE sequences, we performed information content analyses using a group of variant EIAV sequences. Information content analysis is widely used to evaluate sequence conservation in nucleic acid or protein sequences (e.g., [46]–[49]). Sequences of the EIAV gp90 gene, collected for analysis of envelope SU protein variants by Mealey, et al. [42], were aligned and information content (Shannon entropy) was calculated as described in Materials and Methods. Figure 7
RNA structural motifs found within the high affinity Rev-binding sites of HIV-1 and EIAV are also found in other lentiviral RREs To explore the possibility that RNA secondary structural elements required for Rev binding in EIAV might also be found in other lentiviruses, we first asked whether RBR-1 and RBR-2, identified in this study, have any predicted RNA structural features in common with one another or with the previously identified high affinity Rev binding site in HIV-1 RRE (stem-loop IIB) [10], [50]. Pairwise RNA sequence and secondary structure alignments performed using RNAstructure Dynalign [51] failed to identify significant RNA structural similarities in EIAV RBR-1 and RBR-2 (data not shown). In striking contrast, the stem-loop IIB region of HIV-1 and RBR-2 of EIAV, both of which correspond to high affinity Rev binding sites, have potential to form very similar ensembles of secondary structures (two examples are shown in Figure 8A
The unexpected RNA secondary structural similarities detected through pairwise analysis of the Rev-binding domains in HIV-1 and EIAV prompted us to generate a computational RNA structural motif model based on shared features of the two regions using RNAMotif [52]. The resulting RNA motif model was used to scan the complete genomic sequences of 10 different lentiviruses, as well as the recently identified rabbit endogenous lentivirus type K (RELIK) (see Materials and Methods). Most of the genomes, ranging from 7732 to 10,359 nt in length, contain only 1 or 2 copies of the motif (Table S1); Figure 8B Discussion The Rev-responsive element (RRE) is an essential cis-acting RNA regulatory element recognized by the Rev proteins of lentiviruses, including HIV-1 and EIAV. Rev-RRE interactions regulate viral gene expression and genomic replication by mediating the export of incompletely spliced or unspliced lentiviral mRNAs from the nucleus to the cytoplasm of infected host cells [7], [9]. In HIV-1, the RRE secondary structure has been extensively characterized [18], [19], [50], [53] and systematic functional and structural studies have been performed to investigate the detailed mechanism of HIV-1 Rev-RRE interactions [54], [55], [56], [57], [58], [59]. A high-resolution NMR structure for a Rev-RRE complex containing an HIV-1 Rev peptide (27 aa) bound to a synthetic RNA (39 nt) corresponding to its high affinity RRE binding site has been reported [20], but high resolution structures for the complete HIV-1 Rev protein or Rev-RRE complexes are still lacking. A three-dimensional model has been presented for a 56 nt RNA corresponding to HIV-1 RRE domain II [60]. Despite these extensive studies, the extent to which molecular mechanisms that regulate Rev-RRE interactions in HIV-1 are conserved among the lentiviruses is not known. Although previous computational studies identified potential conserved secondary structural elements in lentiviral genomes and RRE regions [25], no information regarding their functions was provided. Here, we provide evidence for involvement of a conserved RNA structural motif in Rev-RRE recognition. By analyzing the RNA secondary structure and Rev binding sites within the RRE of EIAV, the most divergent among known lentiviruses, we identified a RNA structural motif that co-localizes with high affinity Rev binding sites in both HIV-1 and EIAV, and is conserved in several other lentiviruses. These results provide a comparative framework for investigating critical features of Rev-RRE interaction that could be targeted in novel anti-lentiviral therapies. An Experimentally Validated RNA Structure for the EIAV RRE Two important aims of this study were to determine the secondary structure of the EIAV RRE and to obtain high-resolution experimental data regarding Rev-RRE interactions, for comparison with available HIV-1 data. Using a combination of computational and experimental approaches, we generated an optimized RNA secondary structure model for the EIAV ERRE. In the context of this structure, individual ribonucleotides and secondary structural elements that are protected from chemical cleavage or undergo structural transitions upon Rev binding were identified using detailed RNA footprinting experiments. One striking characteristic of our proposed ERRE structure is the relative paucity of stable stem structures and abundance of single-stranded loops, several of which are unusually large. The calculated free energy of the optimized ERRE secondary structure, based on a combination of thermodynamic calculations, chemical probing data and ribonucleotide covariation frequencies using RNAalifold is −77.9 kcal/mol (Figure 3 Two Distinct Rev Binding Domains within the RRE of EIAV The ERRE footprinting experiments provided a detailed view of the interaction between EIAV Rev and RBR-1, which contains the ESE region previously implicated in Rev binding. Within loop B, changes in chemical reactivities of every purine residue in PuA and several As in PuB were detected, consistent with previous studies reporting decreased Rev binding when mutations converting several GAA motifs into GCAs were introduced within PuB [29]. Similarly, EIAV Rev binding activity was virtually abolished when a GAA sequence was changed to GAU in PuB [32]. Both previous studies reported that mutations in PuA had little effect on the binding affinity of EIAV Rev, again consistent with the footprinting results reported here: only a few changes in ribonucleotide accessibilities in this region were detected upon Rev binding. In contrast, Rev binding resulted in significant changes in ribonucleotide accessibilities in a third purine-rich motif, located within loop A (Figure 3 RBR-2, a novel Rev-binding region within the ERRE, was identified as second Rev-mediated footprint, encompassing relatively long tracts of residues protected from hydroxyl radical cleavage and several individual ribonucleotides with enhanced reactivity to kethoxal and DMS. Quantitative in vitro binding assays demonstrated that RBR-2 is required for high affinity binding of EIAV Rev; ERRE fragments containing both RBR-1 and RBR-2 have much higher affinity for EIAV Rev than those lacking RBR-2 (Figure S1). For RBR-2, all computational methods produced the same RNA secondary structure. The Rev-induced footprint in SL-Z (nt 439–462) in RBR-2 is especially interesting because the topology of this stem-loop structure is very similar to that of stem-loop IIB in HIV-I, which corresponds to the primary high-affinity Rev binding site in the HIV-1 RRE [10], [50]. Although the sequences of the two structures differ, they share a strong protection pattern on opposite strands in the stem, characteristic of a “5′ stagger” of 7 nucleotides. A 5′ stagger in the footprinting protection pattern on complementary strands of an RNA duplex suggests interaction of the bound protein within the major groove of the RNA (as in the interaction between ribosomal protein S7 and the 3′ domain of 16S rRNA in E. coli. [62]). This similarity supports the hypothesis that EIAV Rev binds within major groove of the RNA stem-loop structure, SL-Z, in RBR-2 (Figure 5C In HIV-1, an extended RRE sequence that includes structured regions surrounding the stem-loop IIB binding site has been shown to enhance Rev binding and promote its multimerization on HIV-1 RNAs [19], [63]. We have occasionally observed multimerization of EIAV Rev on fragments of ERRE using in vitro binding assays such as UV-crosslinking and EMSA (unpublished data), but we are not aware of any direct evidence for a functional role of EIAV Rev multimerization in vivo. Further investigation will be required to dissect the functional relationships among RBR-1, RBR-2 and the full length EIAV RRE. A Conserved RNA Structural Motif for Rev Recognition in both EIAV and HIV-1 To investigate whether the RBR-2 domain might have RNA structural features in common with the high affinity Rev binding stem-loop IIB region of HIV-1, we performed pairwise comparisons using Dynalign [51]. We found that the two RRE regions can form very similar ensembles of secondary structures (Figure 8A EIAV is genetically the simplest of the exogenous lentiviruses, has the smallest number of genes, and lacks a vif protein [64], [65]. Recently, the first endogenous lentiviruses were discovered and characterized by Katzourakik et al. [66]. Although these endogenous rabbit viruses (RELIKs) are more than 7 million years old, they have retained many lentiviral genomic structural features as well as genes for regulatory proteins such as tat and rev. Interestingly, we found the conserved RNA structural motif in RELIK sequence, also within the env gene region (Figure 8B Materials and Methods Preparation of ERRE RNA and purified EIAV Rev protein The EIAV ERRE was amplified by PCR from pERRE-All [29], [34], [65] using a 5′ primer containing a T7 promoter site. The PCR product was purified using QIAquick PCR purification columns (QIAGEN, Valencia, CA), and RNA was generated by in vitro transcription (T7-MEGAscript; Ambion, Austin, TX). Transcribed RNA was purified using MEGAClear kits (Ambion, Austin, TX), denatured at 90°C for 2 min and annealed by slow cooling. Ethanol precipitation was performed to remove salts and concentrate ERRE RNA. Concentrated RNA was stored at −80°C. EIAV Rev protein was expressed as an MBP-ERev fusion protein and purified as described previously [27]. Chemical probing of RRE RNA secondary structure and footprinting Rev-RRE complexes Prior to chemical probing or footprinting experiments, the annealed ERRE in RNA storage buffer (10 mM Tris-HCl, pH 7.5) was pre-incubated at 42°C for 15 min. To generate unmodified and modified unbound ERRE samples for RNA secondary structure probing experiments, two aliquots (each containing 35 pmol) of ERRE were added to RNA binding buffer (10 mM HEPES-KOH, pH 7.5, 100 mM KCl, 1 mM MgCl2, and 0.5 mM EDTA). To generate ERev-ERRE protein-RNA complexes for footprinting experiments, samples containing one to thirty-fold molar excess of purified MBP-ERev fusion protein were incubated with pre-folded ERRE RNA (35pmol) in binding buffer in a total volume of 87.5 µ for 20 min on ice. Samples containing folded ERRE RNA alone or RNA-protein complexes were incubated with 10.5 µ 880 mM dimethylsulfate (DMS) (Sigma-Aldrich, St. Louis, MO) or 7 µ 720 mM kethoxal (ICN, Costa Mesa, CA) or 16 µ hydroxyl radical probing mixture (4 µ of 50 mM Fe(NH4)2(SO4)2·6H2O, 4 µ of 100 mM EDTA, 4 µ of 250 mM ascorbic acid, and 4 µ of 2.5% hydrogen peroxide) for 10 min at room temperature. DMS modification reactions were stopped by addition of 59.3 µ of DMS stop buffer (1 M Tris-HCl pH 7.5, 0.1 M EDTA pH 8.0, and 1 M 2-mercaptoethanol). For the kethoxal probing, 8.2 µ of 0.5 M potassium borate was added for stabilizing kethoxal. Hydroxyl radical probing reactions were quenched by the addition of 92.8 µ of 1 M thiourea. After ethanol precipitation of RNA or RNA-protein complexes, 3 phenol and 2 chloroform extractions were performed to purify RNA from RNA-protein complexes. RNA was concentrated and washed using 100% and 70% ethanol precipitations. Finally, RNA was resuspended in 35 µ of water (for DMS and hydroxyl radical modifications) or 35 µ of 40 mM potassium borate for kethoxal modification. Additional details are provided in [43].Primer extension analysis of chemically-modified EIAV RRE sequences Nitrocellulose filter binding assays Nitrocellulose filter binding assays were carried out using purified 32P-labelled RNAs corresponding to the ERRE (ERRE_RBR12, 555 nt; 5280 to 5834) or subfragment of the ERRE (ERRE_RBR1, 123 nt; 5443 to 5465) using standard procedures. Binding affinities were calculated using Graphpad Prism 5 software [68]. Sequences of gp90 (SU) variants and information content analysis The EIAV genomic RNA sequences used in the present study were originally collected for analyzing sequence variants in the EIAV Env SU protein by Mealey, et al. [42] and deposited in the NCBI GenBank in two segments (5′ and 3′). From a total of 284 EIAV sequences used in Mealey, et al., those that overlapped the ERRE region were collected. After removal of sequences with deletions or premature stop codons, a total of 258 sequences (126 corresponding to the 5′ fragment and 132 corresponding to the 3′ fragment of SU) corresponding to 139 complete env gene variant sequences, remained. The concept and methods for analysis of information content are described elsewhere [46], [69], [70]. Briefly, collections of the 5′ or 3′ fragment sequences were aligned using CLUSTALW (http://www.ebi.ac.uk/clustalw/) [71] and information content was calculated according to the following equation:
RNA secondary structure prediction Different methods for RNA secondary structure prediction have been reviewed recently [72], [73]. In this work, Mfold [36] was used to predict the lowest free energy secondary structure of the ERRE, using only the standard EIAV sequence as input (i.e., with no experimental constraints). To model the secondary structure of the ERRE, using a single sequence of the ERRE and experimental constraints derived from the results of chemical probing experiments, four different methods were used: Mfold (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1.cgi) [36], Sfold (http://sfold.wadsworth.org) [38], RNAfold (http://www.tbi.univie.ac.at/ivo/RNA/) [40], and RNAStructure (http://rna.urmc.rochester.edu/rnastructure.html) [39]. Experimental constraint data were preprocessed to generate appropriately formatted input files for each of the four programs. A fifth method, RNAalifold, generates an optimal RNA secondary structure based on calculation of the minimum free energy structure, and a partition function and base-pairing probability matrix derived from a multiple sequence alignment (http://www.tbi.univie.ac.at/ivo/RNA/) [41]. Input for RNAalifold consisted of an alignment of 140 ERRE variant sequences generated using CLUSTALW (http://www.ebi.ac.uk/clustalw/) [71]. The resulting alignment and experimental constraint input was used to determine an optimal RNA secondary structure for the ERRE. PSEUDOVIEWER2 (http://wilab.inha.ac.kr/pseudoviewer2/) [74] was used to generate RNA secondary structure diagrams. Identification of a conserved RNA structural motif within lentiviral genomes RNAstructure Dynalign software (http://rna.urmc.rochester.edu/rnastructure.html) [51] was used to test whether sequences corresponding to the high affinity Rev binding sites of EIAV and HIV-1 have the capacity to form similar RNA secondary structures. Sequences of 100 nt regions encompassing the HIV-1 stem-loop IIB region (nt 8–107) and the EIAV RBR-2 region (nt 371–470) were compared, resulting in two very similar ensembles of predicted secondary structures. RNA motif models based on common features of the HIV-1 and EIAV RRE structures were generated using RNAMotif (http://www.scripps.edu/mb/case/casegr-sh-3.5.html) [52], and used to scan the complete genomic sequences of ten different lentiviruses (GenBank accession no. M15654;HIV-1, NC_001450; EIAV, NC_001722; HIV-2, NC_001549; SIV, NC_001452; VV, NC_001463; CAEV, NC_001511; OLV, NC_001482; FIV, NC_001413; BIV, NC_001654; JDV) and rabbit endogenous lentivirus type K (RELIK) [66]. Table S1 Occurrence of conserved RNA structural motifs in lentiviral genomes. (0.02 MB XLS) Click here for additional data file.(24K, xls) Figure S1 Deletion of RBR-2 from EIAV RRE results in loss of high affinity Rev binding in vitro. Quantitative nitrocellulose filter binding assays were performed to measure binding affinity of RNAs that contain both RBR-1 and RBR-2 (ERRE_RBR12, blue) and those that contain only RBR-1 (ERRE_RBR1, red). Purified 32P-labeled RNAs were incubated with increasing concentrations of purified MBP-ERev, and RNA-protein complexes specifically bound to nitrocellulose were separated from unbound RNAs and quantified by scintillation counter. Binding isotherms based on experimental data were fit to models generated using Prism software (http://www.graphpad.com/prism/Prism.htm). Binding constants estimated from these models were: Kd = 19 nM for RNA containing both RBR- and RBR-2 (blue) and Kd = 5200 nM (5.2 µM) for RNA lacking RBR-2 (red).(0.17 MB TIF) Click here for additional data file.(162K, tif) Acknowledgments We thank members of the Culver lab, especially Laura Dutca for advice, technical assistance and reagents used in the chemical probing and primer extension experiments, and members of Dobbs and Culver labs for helpful discussions. We also thank to Ben Lewis for critical reading and reviewers for valuable comments that improved the manuscript. Footnotes Competing Interests: The authors have declared that no competing interests exist. Funding: This work was supported in part by U.S. Public Health Service, National Institutes of Health Grants CA97936, GM066387, National Research Initiative of the USDA Cooperative State Research, Education, and Extension Service Grant 2002-35204-12699, and the Center for Integrated Animal Genomics at Iowa State University. Sponsors played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript. References 1. Schwartz S, Felber BK, Benko DM, Fenyo EM, Pavlakis GN. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol. 1990;64:2519–2529. [PubMed] 2. Stephens RM, Derse D, Rice NR. Cloning and characterization of cDNAs encoding equine infectious anemia virus tat and putative Rev proteins. J Virol. 1990;64:3716–3725. [PubMed] 3. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci. 2000;25:106–110. [PubMed] 4. Wang Z, Xiao X, Van Nostrand E, Burge CB. General and specific functions of exonic splicing silencers in splicing control. Mol Cell. 2006;23:61–70. [PubMed] 5. Ernst RK, Bray M, Rekosh D, Hammarskjold ML. A structured retroviral RNA element that mediates nucleocytoplasmic export of intron-containing RNA. Mol Cell Biol. 1997;17:135–144. [PubMed] 6. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev. 1992;56:375–394. [PubMed] 7. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol. 1998;52:491–532. [PubMed] 8. Stoltzfus CM, Madsen JM. Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr HIV Res. 2006;4:43–55. [PubMed] 9. Hope TJ. The ins and outs of HIV Rev. Arch Biochem Biophys. 1999;365:186–191. [PubMed] 10. Cook KS, Fisk GJ, Hauber J, Usman N, Daly TJ, et al. Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate. Nucleic Acids Res. 1991;19:1577–1583. [PubMed] 11. Zapp ML, Green MR. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature. 1989;342:714–716. [PubMed] 12. Olsen HS, Cochrane AW, Dillon PJ, Nalin CM, Rosen CA. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev. 1990;4:1357–1364. [PubMed] 13. Zapp ML, Hope TJ, Parslow TG, Green MR. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci U S A. 1991;88:7734–7738. [PubMed] 14. Fridell RA, Partin KM, Carpenter S, Cullen BR. Identification of the activation domain of equine infectious anemia virus rev. J Virol. 1993;67:7317–7323. [PubMed] 15. Fridell RA, Bogerd HP, Cullen BR. Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway. Proc Natl Acad Sci U S A. 1996;93:4421–4424. [PubMed] 16. Dillon PJ, Nelbock P, Perkins A, Rosen CA. Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA. J Virol. 1990;64:4428–4437. [PubMed] 17. Le SY, Malim MH, Cullen BR, Maizel JV. A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. Nucleic Acids Res. 1990;18:1613–1623. [PubMed] 18. Kjems J, Brown M, Chang DD, Sharp PA. Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. Proc Natl Acad Sci U S A. 1991;88:683–687. [PubMed] 19. Mann DA, Mikaelian I, Zemmel RW, Green SM, Lowe AD, et al. A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol. 1994;241:193–207. [PubMed] 20. Battiste JL, Mao H, Rao NS, Tan R, Muhandiram DR, et al. Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science. 1996;273:1547–1551. [PubMed] 21. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A. 2002;99:14440–14445. [PubMed] 22. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol. 2007;25:1444–1454. [PubMed] 23. Tiley LS, Cullen BR. Structural and functional analysis of the visna virus Rev-response element. J Virol. 1992;66:3609–3615. [PubMed] 24. Saltarelli M, Querat G, Konings DA, Vigne R, Clements JE. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virology. 1990;179:347–364. [PubMed] 25. Lesnik EA, Sampath R, Ecker DJ. Rev response elements (RRE) in lentiviruses: an RNAMotif algorithm-based strategy for RRE prediction. Med Res Rev. 2002;22:617–636. [PubMed] 26. Foley BT. An overview of the molecular phylogeny of lentiviruses. HIV Sequence Compendium. 2000;2000:35–43. 27. Lee JH, Murphy SC, Belshan M, Sparks WO, Wannemuehler Y, et al. Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain. J Virol. 2006;80:3844–3852. [PubMed] 28. Harris ME, Gontarek RR, Derse D, Hope TJ. Differential requirements for alternative splicing and nuclear export functions of equine infectious anemia virus Rev protein. Mol Cell Biol. 1998;18:3889–3899. [PubMed] 29. Belshan M, Park GS, Bilodeau P, Stoltzfus CM, Carpenter S. Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs. Mol Cell Biol. 2000;20:3550–3557. [PubMed] 30. Liao HJ, Baker CC, Princler GL, Derse D. cis-Acting and trans-acting modulation of equine infectious anemia virus alternative RNA splicing. Virology. 2004;323:131–140. [PubMed] 31. Gontarek RR, Derse D. Interactions among SR proteins, an exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing. Mol Cell Biol. 1996;16:2325–2331. [PubMed] 32. Chung H, Derse D. Binding sites for Rev and ASF/SF2 map to a 55-nucleotide purine-rich exonic element in equine infectious anemia virus RNA. J Biol Chem. 2001;276:18960–18967. [PubMed] 33. Martarano L, Stephens R, Rice N, Derse D. Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing. J Virol. 1994;68:3102–3111. [PubMed] 34. Belshan M, Harris ME, Shoemaker AE, Hope TJ, Carpenter S. Biological characterization of Rev variation in equine infectious anemia virus. J Virol. 1998;72:4421–4426. [PubMed] 35. Belshan M, Baccam P, Oaks JL, Sponseller BA, Murphy SC, et al. Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony. Virology. 2001;279:185–200. [PubMed] 36. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31:3406–3415. [PubMed] 37. Ehresmann C, Baudin F, Mougel M, Romby P, Ebel JP, et al. Probing the structure of RNAs in solution. Nucleic Acids Res. 1987;15:9109–9128. [PubMed] 38. Ding Y, Chan CY, Lawrence CE. Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res. 2004;32:W135–141. [PubMed] 39. Mathews DH, Disney MD, Childs JL, Schroeder SJ, Zuker M, et al. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A. 2004;101:7287–7292. [PubMed] 40. Hofacker IL, Fontana W, Stadler PF, Bonhoeffer S, Tacker M, et al. Fast folding and comparison of RNA secondary structures. Monatshefte f Chemie. 1994;125:167–188. 41. Hofacker IL, Fekete M, Stadler PF. Secondary structure prediction for aligned RNA sequences. J Mol Biol. 2002;319:1059–1066. [PubMed] 42. Mealey RH, Leib SR, Pownder SL, McGuire TC. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection. J Virol. 2004;78:9295–9305. [PubMed] 43. Merryman CN, H. F. New York: Oxford University Press; 1998. Footprinting and modification-interference analysis of binding sites on RNA.: 44. Culver GM, Noller HF. Directed hydroxyl radical probing of RNA from iron(II) tethered to proteins in ribonucleoprotein complexes. Methods Enzymol. 2000;318:461–475. [PubMed] 45. Xu R, Teng J, Cooper TA. The cardiac troponin T alternative exon contains a novel purine-rich positive splicing element. Mol Cell Biol. 1993;13:3660–3674. [PubMed] 46. Peleg O, Brunak S, Trifonov EN, Nevo E, Bolshoy A. RNA secondary structure and squence conservation in C1 region of human immunodeficiency virus type 1 env gene. AIDS Res Hum Retroviruses. 2002;18:867–878. [PubMed] 47. Schneider TD, Stormo GD, Gold L, Ehrenfeucht A. Information content of binding sites on nucleotide sequences. J Mol Biol. 1986;188:415–431. [PubMed] 48. Schneider TD, Stormo GD. Excess information at bacteriophage T7 genomic promoters detected by a random cloning technique. Nucleic Acids Res. 1989;17:659–674. [PubMed] 49. Stephens RM, Schneider TD. Features of spliceosome evolution and function inferred from an analysis of the information at human splice sites. J Mol Biol. 1992;228:1124–1136. [PubMed] 50. Tiley LS, Malim MH, Tewary HK, Stockley PG, Cullen BR. Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci U S A. 1992;89:758–762. [PubMed] 51. Mathews DH, Turner DH. Dynalign: an algorithm for finding the secondary structure common to two RNA sequences. J Mol Biol. 2002;317:191–203. [PubMed] 52. Macke TJ, Ecker DJ, Gutell RR, Gautheret D, Case DA, et al. RNAMotif, an RNA secondary structure definition and search algorithm. Nucleic Acids Res. 2001;29:4724–4735. [PubMed] 53. Heaphy S, Dingwall C, Ernberg I, Gait MJ, Green SM, et al. HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region. Cell. 1990;60(4):685–693. [PubMed] 54. Giver L, Bartel D, Zapp M, Pawul A, Green M, et al. Selective optimization of the Rev-binding element of HIV-1. Nucleic Acids Res. 1993;21(23):5509–5516. [PubMed] 55. Hamm TE, Rekosh D, Hammarskjold ML. Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein. J Virol. 1999;73(7):5741–5747. [PubMed] 56. Iwai S, Pritchard C, Mann DA, Karn J, Gait MJ. Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein. Nucleic Acids Res. 1992;20(24):6465–6472. [PubMed] 57. Kjems J, Frankel AD, Sharp PA. Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. Cell. 1991;67(1):169–178. [PubMed] 58. Kjems J, Calnan BJ, Frankel AD, Sharp PA. Specific binding of a basic peptide from HIV-1 Rev. Embo J. 1992;11(3):1119–1129. [PubMed] 59. Lee SW, Gallardo HF, Gilboa E, Smith C. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol. 1994;68(12):8254–8264. [PubMed] 60. Le SY, Pattabiraman N, Maizel JV., Jr. RNA tertiary structure of the HIV RRE domain II containing non-Watson-Crick base pairs GG and GA: molecular modeling studies. Nucleic Acids Res. 1994;22(19):3966–3976. [PubMed] 61. Mathews DH. Using an RNA secondary structure partition function to determine confidence in base pairs predicted by free energy minimization. Rna. 2004;10:1178–1190. [PubMed] 62. Powers T, Noller HF. Hydroxyl radical footprinting of ribosomal proteins on 16S rRNA. Rna. 1995;1:194–209. [PubMed] 63. Jain C, Belasco JG. Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol Cell. 2001;7:603–614. [PubMed] 64. Rushlow K, Olsen K, Stiegler G, Payne SL, Montelaro RC, et al. Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus. Virology. 1986;155:309–321. [PubMed] 65. Kawakami T, Sherman L, Dahlberg J, Gazit A, Yaniv A, et al. Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. Virology. 1987;158:300–312. [PubMed] 66. Katzourakis A, Tristem M, Pybus OG, Gifford RJ. Discovery and analysis of the first endogenous lentivirus. Proc Natl Acad Sci U S A. 2007;104:6261–6265. [PubMed] 67. Moazed D, Stern S, Noller HF. Rapid chemical probing of conformation in 16 S ribosomal RNA and 30 S ribosomal subunits using primer extension. J Mol Biol. 1986;187:399–416. [PubMed] 69. Shannon CE. A mathematical theory of communication. The Bell System Technical Journal. 1948;27:379–423. 623-656. 70. Chaitin GJ. Algorithmic information theory. Encyclopedia of Statistical Sciences. 1982;1:38–41. 71. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–4680. [PubMed] 72. Mathews DH. Revolutions in RNA secondary structure prediction. J Mol Biol. 2006;359:526–532. [PubMed] 73. Mathews DH, Turner DH. Prediction of RNA secondary structure by free energy minimization. Curr Opin Struct Biol. 2006;16:270–278. [PubMed] 74. Han K, Byun Y. PSEUDOVIEWER2: Visualization of RNA pseudoknots of any type. Nucleic Acids Res. 2003;31:3432–3440. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
J Virol. 1990 Jun; 64(6):2519-29.
[J Virol. 1990]J Virol. 1990 Aug; 64(8):3716-25.
[J Virol. 1990]Trends Biochem Sci. 2000 Mar; 25(3):106-10.
[Trends Biochem Sci. 2000]Mol Cell. 2006 Jul 7; 23(1):61-70.
[Mol Cell. 2006]Mol Cell Biol. 1997 Jan; 17(1):135-44.
[Mol Cell Biol. 1997]Arch Biochem Biophys. 1999 May 15; 365(2):186-91.
[Arch Biochem Biophys. 1999]Nucleic Acids Res. 1991 Apr 11; 19(7):1577-83.
[Nucleic Acids Res. 1991]Nature. 1989 Dec 7; 342(6250):714-6.
[Nature. 1989]Genes Dev. 1990 Aug; 4(8):1357-64.
[Genes Dev. 1990]Proc Natl Acad Sci U S A. 1991 Sep 1; 88(17):7734-8.
[Proc Natl Acad Sci U S A. 1991]Nature. 1989 Dec 7; 342(6250):714-6.
[Nature. 1989]J Virol. 1990 Sep; 64(9):4428-37.
[J Virol. 1990]Nucleic Acids Res. 1990 Mar 25; 18(6):1613-23.
[Nucleic Acids Res. 1990]J Virol. 1992 Jun; 66(6):3609-15.
[J Virol. 1992]Virology. 1990 Nov; 179(1):347-64.
[Virology. 1990]J Virol. 1993 Dec; 67(12):7317-23.
[J Virol. 1993]J Virol. 2006 Apr; 80(8):3844-52.
[J Virol. 2006]Mol Cell Biol. 1998 Jul; 18(7):3889-99.
[Mol Cell Biol. 1998]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]Virology. 2004 May 20; 323(1):131-40.
[Virology. 2004]J Virol. 1998 May; 72(5):4421-6.
[J Virol. 1998]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Biol Chem. 2001 Jun 1; 276(22):18960-7.
[J Biol Chem. 2001]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]Mol Cell Biol. 1996 May; 16(5):2325-31.
[Mol Cell Biol. 1996]J Virol. 1994 May; 68(5):3102-11.
[J Virol. 1994]J Virol. 1998 May; 72(5):4421-6.
[J Virol. 1998]Virology. 2004 May 20; 323(1):131-40.
[Virology. 2004]Nucleic Acids Res. 2003 Jul 1; 31(13):3406-15.
[Nucleic Acids Res. 2003]Nucleic Acids Res. 1987 Nov 25; 15(22):9109-28.
[Nucleic Acids Res. 1987]Nucleic Acids Res. 2004 Jul 1; 32(Web Server issue):W135-41.
[Nucleic Acids Res. 2004]Proc Natl Acad Sci U S A. 2004 May 11; 101(19):7287-92.
[Proc Natl Acad Sci U S A. 2004]Nucleic Acids Res. 2003 Jul 1; 31(13):3406-15.
[Nucleic Acids Res. 2003]Nucleic Acids Res. 2004 Jul 1; 32(Web Server issue):W135-41.
[Nucleic Acids Res. 2004]Proc Natl Acad Sci U S A. 2004 May 11; 101(19):7287-92.
[Proc Natl Acad Sci U S A. 2004]J Mol Biol. 2002 Jun 21; 319(5):1059-66.
[J Mol Biol. 2002]J Virol. 2004 Sep; 78(17):9295-305.
[J Virol. 2004]J Virol. 2006 Apr; 80(8):3844-52.
[J Virol. 2006]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Biol Chem. 2001 Jun 1; 276(22):18960-7.
[J Biol Chem. 2001]J Mol Biol. 2002 Jun 21; 319(5):1059-66.
[J Mol Biol. 2002]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Biol Chem. 2001 Jun 1; 276(22):18960-7.
[J Biol Chem. 2001]Methods Enzymol. 2000; 318():461-75.
[Methods Enzymol. 2000]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Biol Chem. 2001 Jun 1; 276(22):18960-7.
[J Biol Chem. 2001]Mol Cell Biol. 1996 May; 16(5):2325-31.
[Mol Cell Biol. 1996]Mol Cell Biol. 1993 Jun; 13(6):3660-74.
[Mol Cell Biol. 1993]J Virol. 2006 Apr; 80(8):3844-52.
[J Virol. 2006]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Biol Chem. 2001 Jun 1; 276(22):18960-7.
[J Biol Chem. 2001]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]AIDS Res Hum Retroviruses. 2002 Aug 10; 18(12):867-78.
[AIDS Res Hum Retroviruses. 2002]J Mol Biol. 1992 Dec 20; 228(4):1124-36.
[J Mol Biol. 1992]J Virol. 2004 Sep; 78(17):9295-305.
[J Virol. 2004]J Virol. 1990 Aug; 64(8):3716-25.
[J Virol. 1990]J Virol. 2004 Sep; 78(17):9295-305.
[J Virol. 2004]Nucleic Acids Res. 1991 Apr 11; 19(7):1577-83.
[Nucleic Acids Res. 1991]Proc Natl Acad Sci U S A. 1992 Jan 15; 89(2):758-62.
[Proc Natl Acad Sci U S A. 1992]J Mol Biol. 2002 Mar 22; 317(2):191-203.
[J Mol Biol. 2002]J Mol Biol. 2002 Mar 22; 317(2):191-203.
[J Mol Biol. 2002]Nucleic Acids Res. 2001 Nov 15; 29(22):4724-35.
[Nucleic Acids Res. 2001]Annu Rev Microbiol. 1998; 52():491-532.
[Annu Rev Microbiol. 1998]Arch Biochem Biophys. 1999 May 15; 365(2):186-91.
[Arch Biochem Biophys. 1999]Proc Natl Acad Sci U S A. 1991 Feb 1; 88(3):683-7.
[Proc Natl Acad Sci U S A. 1991]J Mol Biol. 1994 Aug 12; 241(2):193-207.
[J Mol Biol. 1994]Proc Natl Acad Sci U S A. 1992 Jan 15; 89(2):758-62.
[Proc Natl Acad Sci U S A. 1992]Proc Natl Acad Sci U S A. 2004 May 11; 101(19):7287-92.
[Proc Natl Acad Sci U S A. 2004]RNA. 2004 Aug; 10(8):1178-90.
[RNA. 2004]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Biol Chem. 2001 Jun 1; 276(22):18960-7.
[J Biol Chem. 2001]Nucleic Acids Res. 1991 Apr 11; 19(7):1577-83.
[Nucleic Acids Res. 1991]Proc Natl Acad Sci U S A. 1992 Jan 15; 89(2):758-62.
[Proc Natl Acad Sci U S A. 1992]RNA. 1995 Apr; 1(2):194-209.
[RNA. 1995]Science. 1996 Sep 13; 273(5281):1547-51.
[Science. 1996]J Mol Biol. 1994 Aug 12; 241(2):193-207.
[J Mol Biol. 1994]Mol Cell. 2001 Mar; 7(3):603-14.
[Mol Cell. 2001]J Mol Biol. 2002 Mar 22; 317(2):191-203.
[J Mol Biol. 2002]Virology. 1986 Dec; 155(2):309-21.
[Virology. 1986]Virology. 1987 Jun; 158(2):300-12.
[Virology. 1987]Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6261-5.
[Proc Natl Acad Sci U S A. 2007]Mol Cell Biol. 2000 May; 20(10):3550-7.
[Mol Cell Biol. 2000]J Virol. 1998 May; 72(5):4421-6.
[J Virol. 1998]Virology. 1987 Jun; 158(2):300-12.
[Virology. 1987]J Virol. 2006 Apr; 80(8):3844-52.
[J Virol. 2006]J Mol Biol. 1986 Feb 5; 187(3):399-416.
[J Mol Biol. 1986]J Virol. 2004 Sep; 78(17):9295-305.
[J Virol. 2004]AIDS Res Hum Retroviruses. 2002 Aug 10; 18(12):867-78.
[AIDS Res Hum Retroviruses. 2002]Nucleic Acids Res. 1994 Nov 11; 22(22):4673-80.
[Nucleic Acids Res. 1994]J Mol Biol. 2006 Jun 9; 359(3):526-32.
[J Mol Biol. 2006]Proc Natl Acad Sci U S A. 2004 May 11; 101(19):7287-92.
[Proc Natl Acad Sci U S A. 2004]Nucleic Acids Res. 2003 Jul 1; 31(13):3406-15.
[Nucleic Acids Res. 2003]Nucleic Acids Res. 2004 Jul 1; 32(Web Server issue):W135-41.
[Nucleic Acids Res. 2004]J Mol Biol. 2002 Jun 21; 319(5):1059-66.
[J Mol Biol. 2002]J Mol Biol. 2002 Mar 22; 317(2):191-203.
[J Mol Biol. 2002]Nucleic Acids Res. 2001 Nov 15; 29(22):4724-35.
[Nucleic Acids Res. 2001]Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6261-5.
[Proc Natl Acad Sci U S A. 2007]